New York applications ongoing until September 12th

Learn more about investing in Liberum Bio

Our team will get back to you soon to follow up on your inquiry.
Lead Rounds?
Liberum Bio
Doing for pathway engineering what the desktop printer did for 'zines.
* Data source: Crunchbase
Funding to Date*
Aidan Tinafar, CEO
While Twist and Illumina dominate the DNA sequencing and synthesis markets, there is still a bottleneck in recombinant protein production. We want to fill that void.
By 2025, the recombinant protein market is expected to reach $400 billion.

Today, to produce any sort of custom recombinant protein, it takes weeks. This dramatically slows down scientists’ ability to test, iterate, and improve. Liberum’s affordable, benchtop protein printer will cut that time down to a few hours.